whitepaper

Application note: Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay

Posted: 22 June 2021 | | No comments yet

We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.

In this application note, conducted by a high-throughput screening (HTS) drug discovery group from our customer Idorsia Pharmaceuticals Ltd, we demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility. With pulsed injections of each sample at a single concentration, contact times are reduced, preserving target proteins, enabling longer runs and measuring hundreds of interactions in days rather than weeks.












    To read this application note in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Creoptix

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend